We are testing how well different doses of BI 764532 work with chemotherapy for people with advanced neuroendocrine cancers. The goal is to see which doses are best tolerated by patients.
Health conditions and diseases that the clinical trial is designed to study and treat.
Neuroendocrine carcinoma (NEC) is a type of cancer that arises from neuroendocrine cells, which are found throughout the body. These tumors can occur in various locations, including the lungs and gastrointestinal tract, and may present with symptoms depending on their location and hormone production.
Extra-pulmonary neuroendocrine carcinoma (epNEC) refers to neuroendocrine tumors that occur outside the lungs, often in the gastrointestinal tract or other organs. Symptoms can vary widely based on the tumor's location and function.
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive form of lung cancer that originates from neuroendocrine cells in the lungs. It can lead to respiratory symptoms and is often diagnosed at an advanced stage.
Neuroendocrine carcinoma with an unknown primary site is a diagnosis where neuroendocrine tumors are found, but the original site of the tumor cannot be identified. This can complicate treatment and management.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
